11/13
01:26 pm
aclx
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice [Yahoo! Finance]
Medium
Report
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice [Yahoo! Finance]
11/12
12:36 pm
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Truist Financial Co. from $87.00 to $136.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Truist Financial Co. from $87.00 to $136.00. They now have a "buy" rating on the stock.
11/8
10:59 am
aclx
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
11/7
06:40 pm
aclx
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
04:00 pm
aclx
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
Medium
Report
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at HC Wainwright from $80.00 to $95.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at HC Wainwright from $80.00 to $95.00. They now have a "buy" rating on the stock.
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Robert W. Baird from $77.00 to $106.00. They now have an "outperform" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Robert W. Baird from $77.00 to $106.00. They now have an "outperform" rating on the stock.
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Bank of America Co. from $84.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Bank of America Co. from $84.00 to $100.00. They now have a "buy" rating on the stock.
11/6
08:06 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Morgan Stanley from $81.00 to $106.00. They now have an "overweight" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Morgan Stanley from $81.00 to $106.00. They now have an "overweight" rating on the stock.
11/5
09:18 am
aclx
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World [Yahoo! Finance]
Low
Report
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World [Yahoo! Finance]
11/5
09:00 am
aclx
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
Medium
Report
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
10/31
10:58 pm
aclx
Arcellx (ACLX) Surged in Q3. Here's Why [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Surged in Q3. Here's Why [Yahoo! Finance]
10/31
08:35 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
10/18
03:33 pm
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC.
10/18
10:57 am
aclx
Baron Health Care Fund Q3 2024 Shareholder Letter [Seeking Alpha]
Low
Report
Baron Health Care Fund Q3 2024 Shareholder Letter [Seeking Alpha]
10/18
10:35 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Stifel Nicolaus from $83.00 to $122.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Stifel Nicolaus from $83.00 to $122.00. They now have a "buy" rating on the stock.
10/17
09:38 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $85.00 to $115.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $85.00 to $115.00. They now have a "buy" rating on the stock.
10/8
07:32 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $109.00 price target on the stock.
Medium
Report
Arcellx, Inc. (NASDAQ: ACLX) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $109.00 price target on the stock.
9/10
08:48 am
aclx
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma [Seeking Alpha]
Low
Report
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma [Seeking Alpha]
9/9
01:03 pm
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/3
08:03 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Arcellx, Inc. (NASDAQ: ACLX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.